3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Breast
1
Conditions
Colorectal Neoplasms
35
Glioblastoma
24
Carcinoma, Non-Small-Cell Lung
21
Ovarian Neoplasms
14
Carcinoma, Hepatocellular
14
Brain Neoplasms
14
Carcinoma, Renal Cell
13
Pancreatic Neoplasms
12
Neoplasms
10
Neoplasm Metastasis
10
Glioma
10
Breast Neoplasms
10
Colonic Neoplasms
8
Astrocytoma
8
Melanoma
7
Uterine Cervical Neoplasms
6
Rectal Neoplasms
6
Liver Neoplasms
6
Gliosarcoma
6
Endometrial Neoplasms
6
Stomach Neoplasms
5
Lung Neoplasms
5
Fallopian Tube Neoplasms
5
Colorectal Cancer Metastatic
5
Advanced Solid Tumors
5
Squamous Cell Carcinoma of Head and Neck
4
Prostatic Neoplasms
4
Oligodendroglioma
4
Triple Negative Breast Neoplasms
3
Small Cell Lung Carcinoma
3
Interventions
pembrolizumab
3
Paclitaxel
2
Carboplatin
2
sacituzumab govitecan
1
osimertinib
1
olaparib
1
ferumoxtran-10
1
dostarlimab
1
cobimetinib
1
cemiplimab
1
VMBP protocol
1
Taxes
1
Immunoglobulin G
1
Imatinib Mesylate
1
D-methadone
1
Cisplatin
1
Bevacizumab
1
Axitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Uterine Neoplasms
×
Bevacizumab
×
Clear all
NCT05579366
2026-06-03
RAINFOL-01
Genmab
Phase 1/2
Recruiting
884 enrolled